Clinical Trials Browser

Active not recruiting × lazertinib × Clear all

NCT02609776 2026-04-13

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-04-13

Chrysalis-2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-04-13

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT05786430 2026-01-27

LUCAS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05299125 2025-10-01

AMIGO-1

Phase 2 Active not recruiting

Metastatic Non-small Cell Lung Cancers

NCT04248829 2024-12-03

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Active not recruiting

393 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung